Financial reports
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
10-K
2022 FY
Annual report
28 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
3 May 22
10-K
2021 FY
Annual report
29 Mar 22
10-Q
2021 Q3
Quarterly report
2 Nov 21
10-Q
2021 Q2
Quarterly report
27 Jul 21
10-Q
2021 Q1
Quarterly report
13 May 21
Current reports
8-K
Bankruptcy or Receivership
29 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
11 Sep 23
8-K
Cost Associated with Exit or Disposal Activities
1 Sep 23
8-K
Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan
25 Jul 23
8-K
Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma
24 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
14 Jul 23
8-K
Other Events
3 Jul 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 Jun 23
8-K
Overview and Update on Pending Merger to Advance Three Promising Clinical
20 Jun 23
Registration and prospectus
25-NSE
Exchange delisting
20 Nov 23
425
Business combination disclosure
3 Jul 23
425
Business combination disclosure
20 Jun 23
S-8
Registration of securities for employees
28 Mar 23
425
Business combination disclosure
28 Mar 23
425
Business combination disclosure
23 Feb 23
425
Business combination disclosure
23 Feb 23
S-8
Registration of securities for employees
16 Jun 22
S-8
Registration of securities for employees
2 Nov 21
S-8
Registration of securities for employees
2 Aug 21
Proxies
DEFA14A
Additional proxy soliciting materials
10 Jul 23
DEFA14A
Additional proxy soliciting materials
5 Jul 23
DEFA14A
Additional proxy soliciting materials
3 Jul 23
DEFA14A
Additional proxy soliciting materials
29 Jun 23
DEFA14A
Additional proxy soliciting materials
27 Jun 23
DEFA14A
Additional proxy soliciting materials
21 Jun 23
DEFA14A
Additional proxy soliciting materials
20 Jun 23
DEFA14A
Additional proxy soliciting materials
16 Jun 23
DEFA14A
Additional proxy soliciting materials
16 Jun 23
DEFA14A
Additional proxy soliciting materials
6 Jun 23
Other
EFFECT
Notice of effectiveness
24 May 21
CORRESP
Correspondence with SEC
19 May 21
UPLOAD
Letter from SEC
18 May 21
CT ORDER
Confidential treatment order
26 Jun 20
CT ORDER
Confidential treatment order
19 Feb 20
EFFECT
Notice of effectiveness
30 Apr 19
CORRESP
Correspondence with SEC
25 Apr 19
CT ORDER
Confidential treatment order
20 Jul 18
EFFECT
Notice of effectiveness
11 May 18
CORRESP
Correspondence with SEC
8 May 18
Ownership
4
Adelene Q Perkins
12 Sep 23
SC 13G/A
Polar Capital Holdings Plc
14 Feb 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
4
Stephane Peluso
4 Aug 22
SC 13G
BlackRock Inc.
8 Jul 22
4
ANTHONY B EVNIN
16 Jun 22
4
DAVID W BEIER
16 Jun 22
4
RICHARD GAYNOR
16 Jun 22
4
Samuel Agresta
16 Jun 22
4
NORMAN C SELBY
16 Jun 22